Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation

Yuhong Jiang(Southwest Jiaotong University), Canquan Mao(Southwest Jiaotong University)

Frontiers in Pharmacology

April 22, 2021

10.3389/fphar.2021.625289

Cited by 24

Related Papers

A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells

|Journal of Pharmacology and Experimental Therapeutics|2017|66

Genome editing of PAR2 through targeted delivery of CRISPR-Cas9 system for alleviating acute lung inflammation via ERK/NLRP3/IL-1β and NO/iNOS signalling

|Acta Pharmaceutica Sinica B|2023|11

Dual‐functional Nanosized Albumin Facilitates CRISPR‐Cas9‐PAR2 to Mitigate Cytokine Storm via TLR4 and Pyroptosis Signaling

|Small|2024|5